Shortened irradiation scheme, continuous infusion of @entity1487 and fractionation of @entity1138 in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of XXXX . Radiotherapy and Gastrointestinal Cooperative Groups.

@entity1 @entity137 @entity5 @entity1138 @entity294 @entity1139 @entity1487
The European Organization for Research and Treatment of @entity5 (EORTC) 22861 randomised trial established that combined radiochemotherapy is the standard treatment for locally advanced @entity5 . This EORTC phase II study (#22953) tests the feasibility of reducing the gap between sequences to 2 weeks, to deliver @entity1138 ( @entity1139 ) in each radiotherapy sequence and @entity1487 continuously during the treatment. The first sequence consisted of 36 Gy over 4 weeks. @entity1487 200 mg/m(2)/days 1-26, @entity1139 10 mg/m(2)/day 1 gap 16 days. Then a second sequence of 23.4 Gy over 17 days, @entity1487 200 mg/m(2)/days 1-17 and, @entity1139 10 mg/m(2)/day 1 was given. 43 @entity1 with a World Health Organization (WHO) status of 0 (n=27) or 1 (n=16) and with T2-T4, N0-3 @entity5 were included. Compliance with the planned treatment, doses and duration was 93%. The complete response rate was 90.7%. Grade 3 @entity137 of 28, 12 and 2% were observed for skin, @entity294 and haematological @entity137 , respectively. The 3-year estimated rates for trials 22861 and 22953 are: 68 and 88% for local control; 72 and 81% for colostomy-free interval, 62 and 84% for severe late @entity137 -free interval, and 70 and 81% for survival, respectively. The 22953 scheme is feasible and the results are promising. This is now considered as the new standard scheme by the EORTC.
